Rhumbline Advisers Raises Holdings in Denali Therapeutics Inc. (NASDAQ:DNLI)

Rhumbline Advisers boosted its position in Denali Therapeutics Inc. (NASDAQ:DNLI) by 13.3% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The fund owned 194,859 shares of the company’s stock after acquiring an additional 22,900 shares during the quarter. Rhumbline Advisers owned 0.14% of Denali Therapeutics worth $4,525,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently added to or reduced their stakes in the company. Zurcher Kantonalbank Zurich Cantonalbank lifted its stake in shares of Denali Therapeutics by 5.5% in the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 26,403 shares of the company’s stock valued at $613,000 after purchasing an additional 1,372 shares in the last quarter. MONECO Advisors LLC acquired a new position in Denali Therapeutics during the second quarter valued at approximately $202,000. Hamilton Lane Advisors LLC purchased a new stake in Denali Therapeutics during the second quarter worth approximately $596,000. SG Americas Securities LLC increased its position in shares of Denali Therapeutics by 93.4% in the second quarter. SG Americas Securities LLC now owns 13,808 shares of the company’s stock worth $321,000 after acquiring an additional 6,667 shares in the last quarter. Finally, Clarius Group LLC increased its position in shares of Denali Therapeutics by 4.5% in the second quarter. Clarius Group LLC now owns 409,995 shares of the company’s stock worth $9,520,000 after acquiring an additional 17,777 shares in the last quarter. Hedge funds and other institutional investors own 92.92% of the company’s stock.

Denali Therapeutics Trading Up 10.1 %

Denali Therapeutics stock opened at $30.77 on Monday. The stock has a 50 day moving average of $23.87 and a 200-day moving average of $21.13. The stock has a market cap of $4.41 billion, a P/E ratio of -32.05 and a beta of 1.37. Denali Therapeutics Inc. has a 52 week low of $14.56 and a 52 week high of $31.00.

Denali Therapeutics (NASDAQ:DNLI) last posted its quarterly earnings data on Thursday, August 1st. The company reported ($0.59) EPS for the quarter, beating analysts’ consensus estimates of ($0.68) by $0.09. The company had revenue of $1.00 million for the quarter, compared to the consensus estimate of $10.00 million. The company’s revenue was down 99.7% compared to the same quarter last year. During the same quarter last year, the company earned $1.30 earnings per share. As a group, equities analysts predict that Denali Therapeutics Inc. will post -2.54 earnings per share for the current fiscal year.

Insider Transactions at Denali Therapeutics

In related news, Director Steve E. Krognes sold 30,000 shares of the business’s stock in a transaction dated Monday, July 1st. The stock was sold at an average price of $22.12, for a total value of $663,600.00. Following the completion of the sale, the director now directly owns 34,404 shares of the company’s stock, valued at $761,016.48. The sale was disclosed in a filing with the SEC, which can be accessed through this link. Corporate insiders own 7.90% of the company’s stock.

Analysts Set New Price Targets

A number of brokerages recently weighed in on DNLI. JPMorgan Chase & Co. upped their price target on shares of Denali Therapeutics from $28.00 to $29.00 and gave the stock an “overweight” rating in a research report on Wednesday, July 10th. Wedbush decreased their target price on Denali Therapeutics from $30.00 to $26.00 and set an “outperform” rating for the company in a research report on Friday, August 2nd. Bank of America raised their target price on Denali Therapeutics from $25.00 to $29.00 and gave the company a “buy” rating in a report on Wednesday, September 4th. HC Wainwright reissued a “buy” rating and set a $90.00 price target on shares of Denali Therapeutics in a research report on Wednesday, September 4th. Finally, Citigroup increased their price objective on shares of Denali Therapeutics from $26.00 to $32.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. One research analyst has rated the stock with a hold rating and eight have given a buy rating to the stock. According to data from MarketBeat.com, the stock presently has a consensus rating of “Moderate Buy” and a consensus price target of $38.33.

Denali Therapeutics Profile

Denali Therapeutics Inc, a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2.